Could a new drug calm the gut and stop IBS pain?
NCT ID NCT07655375
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether a new drug called UCB8600 can stop mast cells in the gut from overreacting, which may cause pain in people with irritable bowel syndrome (IBS). Researchers will take gut tissue from 60 people (some with IBS, some healthy) and treat it with UCB8600 in the lab. They will then measure how many mast cells are activated. This is a very early, lab-based study to see if the drug works as hoped.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UCB8600
What this could lead to
If successful, this could point toward a new treatment for IBS by reducing mast cell activation and easing abdominal pain.
What could go wrong
This is a very early lab study using tissue samples, not a full clinical trial in patients. It may not translate into an effective treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IBS (IRRITABLE BOWEL SYNDROME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospitals Leuven
Leuven, Vlaams-Brabant, 3000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••